Results 51 to 60 of about 1,460,729 (292)

The impact of pre‐biopsy MRI and additional testing on prostate cancer screening outcomes: A rapid review

BJUI Compass
Objective This work aims to examine the latest evidence on the impact of pre‐biopsy MRI, in addition to prostate‐specific antigen (PSA) testing, on health outcomes and quality of life.
Abel Tesfai, Natalia Norori, Thomas A. Harding, Yui Hang Wong, Matthew David Hobbs   +4 more
doaj   +1 more source

Conducting Clinical Research in Low Research Resource Countries: Lessons Learned From the International Registry of Men With Advanced Prostate Cancer Study in Nigeria

JCO Global Oncology
PURPOSEThere is limited cancer clinical research in sub-Saharan African countries despite the significant burden of cancers. The primary objective of this strengths, weaknesses, opportunities, and threats (SWOT) analysis was to understand and document ...
Opeyemi Bolajoko, Parisa Fathi, Dottington Fulwood, Oluwaseyi Toye, Ademola Popoola, Hassan Dogo, Haruna Nggada, Chidiebere Ogo, Omolara Fatiregun, Mohammed Faruk, Lateef Abiodun, Anthonia Sowunmi, Catherine A. Oladoyinbo, Folakemi Odedina   +13 more
doaj   +1 more source

The Influence of Transrectal Multifocal Prostate Biopsy Under Ultrasound Control on the Degree of Infravesical Obstruction in Different Groups of Patients [PDF]

, 2016
. Prostate cancer - is a Malignant neoplasm arising from prostatic epithelium. [1] It is well known, that prostate cancer is the most common cancer in men population.
Avakyan, A. (Armen), Gevorkyan, A. (Ashot), Lumpov, I. (Ilya)   +2 more
core  

Sexual well-being and diurnal cortisol after prostate cancer treatment. [PDF]

, 2020
Sexual dysfunction and psychological distress are common after prostate cancer. Research has not examined the role of neuroendocrine markers of stress (e.g. cortisol).
Gaffey, Allison E, Hoyt, Michael A, Lawsin, Catalina J, Litwin, Mark S, Wang, Ashley W   +4 more
core  

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source

Novel tumor suppressor microRNA at frequently deleted chromosomal region 8p21 regulates epidermal growth factor receptor in prostate cancer. [PDF]

, 2016
Genomic loss of chromosome (chr) 8p21 region, containing prostate-specific NKX3.1 gene, is a frequent alteration of the prostate cancer (PCa) oncogenome.
Bucay, Nathan, Dahiya, Rajvir, Deng, Guoren, Greene, Kirsten, Majid, Shahana, Saini, Sharanjot, Sekhon, Kirandeep, Shahryari, Varahram, Tabatabai, Z Laura, Tanaka, Yuichiro, Yamamura, Soichiro   +10 more
core   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors

Cells, 2022
The mutation-driven transformation of clinical anti-androgen drugs into agonists of the human androgen receptor (AR) represents a major challenge for the treatment of prostate cancer patients. To address this challenge, we have developed a novel class of
Mariia Radaeva, Huifang Li, Eric LeBlanc, Kush Dalal, Fuqiang Ban, Fabrice Ciesielski, Bonny Chow, Helene Morin, Shannon Awrey, Kriti Singh, Paul S. Rennie, Nada Lallous, Artem Cherkasov   +12 more
doaj   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Tyrol Prostate Cancer Demonstration Project : early detection, treatment, outcome, incidence and mortality [PDF]

, 2008
This study aimed to evaluate the effectiveness of a well-controlled programme of early detection and treatment of prostate cancer in the population of Tyrol, Austria, where such a programme of early detection and treatment was initiated in 1988 and where
Bartsch, Georg, Bektic, Jasmin, Boniol, Mathieu, Boyle, Peter, Frauscher, Ferdinand, Horninger, Wolfgang, Klocker, Helmut, Oberaigner, Wilhelm, Pelzer, Alexandre, Robertson, Chris, Schafer, Georg, Schennach, Harald, Severi, Gianluca, Tyrol Prostate Canc Screening Grp   +13 more
core   +1 more source